

Norimitsu Kasahara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/943606/publications.pdf>

Version: 2024-02-01

14
papers

186
citations

1478505

6
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

297
citing authors

#	ARTICLE	IF	CITATIONS
1	A case of a patient with neurofibromatosis type I who developed pneumothorax and eosinophilic pleural effusion after suffering from COVID-19 pneumonia. <i>Radiology Case Reports</i> , 2021, 16, 3504-3508.	0.6	3
2	Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5956.	3.7	13
3	Efficacy and safety of S $\text{â€}1$ monotherapy in previously treated elderly patients (aged $\text{â‰¥}75\text{â‰}percent$ years) with non â€ small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2020, 11, 2867-2876.	1.9	4
4	Successful afatinib rechallenge in a patient with non â€ small cell lung cancer harboring EGFR G719C and S768I mutations. <i>Thoracic Cancer</i> , 2020, 11, 2351-2356.	1.9	4
5	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non â€ small cell lung cancer receiving EGFR â€ TKI treatment. <i>Thoracic Cancer</i> , 2020, 11, 2188-2195.	1.9	11
6	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 761-771.	2.3	32
7	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. <i>Supportive Care in Cancer</i> , 2020, 28, 4825-4831.	2.2	8
8	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. <i>Anticancer Research</i> , 2020, 40, 1571-1578.	1.1	0
9	Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 180-186.	2.0	25
10	Dual inhibition of MEK and p38 impairs tumor growth in KRAS â€ mutated non â€ small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 3569-3575.	1.8	6
11	Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1. <i>Anticancer Research</i> , 2019, 39, 1455-1461.	1.1	31
12	Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, S628-S632.	1.0	3
13	Correlation of tumor-related immunity with ^{18}F -FDG-PET in pulmonary squamous-cell carcinoma. <i>Lung Cancer</i> , 2018, 119, 71-77.	2.0	46
14	Association of ^{18}F -FDG uptake on PET with PD-L1 expression in patients with non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, e24138-e24138.	1.6	0